Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waxman’s Generic Reform: No 30-Month Stay, Early Declaratory Judgements

This article was originally published in The Tan Sheet

Executive Summary

Rep. Henry Waxman (D-Calif.) is developing generic drug reform legislation that would eliminate the 30-month stay of approvals on ANDAs subject to patent litigation
Advertisement

Related Content

FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA
FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA
FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA
Generic Drug Reforms: FTC Notification Bill Appears Ready To Move In 2003
Hatch/Waxman Reform Should Await Pending Supreme Court Decision – Hatch
Hatch/Waxman Reform Should Await Pending Supreme Court Decision – Hatch

Topics

Advertisement
UsernamePublicRestriction

Register

PS095096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel